Novo Nordisk's Wegovy (semaglutide) has become the first GLP-1 RA therapy approved in China for MASH, extending the drug's label beyond weight management and cardiovascular health into liver disease. The clearance gives Novo a first-mover position against Eli Lilly, Pfizer and Innovent in a Chinese GLP-1 market that J.P. Morgan estimates could reach 30 billion yuan within five to seven years.
Novo Nordisk said China's drug regulator approved semaglutide (Wegovy) for metabolic dysfunction-associated steatohepatitis, making it the first GLP-1 RA class therapy cleared for the liver disease in the world's second-largest pharmaceutical market.
"The liver health-related benefits evidence extends the established evidence for Wegovy from weight management and cardiovascular health to liver health, further supporting its role in the comprehensive management of obesity and related complications," the Bagsvaerd, Denmark-based company said in a statement on Thursday.
The approval adds a third indication in China for the once-weekly injectable, which was already cleared there for chronic weight management. MASH, formerly called non-alcoholic steatohepatitis, is a progressive fatty liver disease with no approved GLP-1 therapy in the country before this decision. Novo did not disclose the number of Chinese patients covered by the label, pricing, or a launch date.
The commercial case rests on scale. China's National Health Commission has said more than 65% of the population could be overweight or obese by 2030. Yang Huang, head of China healthcare research at J.P. Morgan, told Reuters he estimates Chinese sales of GLP-1 weight-management therapies could reach 30 billion yuan, or about $4.46 billion, within five to seven years, up from a current market of 3 billion to 4 billion yuan.
Novo's head start is the asset rivals cannot buy. Eli Lilly, Pfizer and China-based Innovent Biologics are all competing with injectable GLP-1 weight-management products in the country, but none holds a MASH label there. Novo has separately filed for an oral Wegovy formulation in China, and the regulator has accepted that marketing application — an early milestone, not an approval, with no timeline disclosed.
The MASH clearance also extends a pattern Novo has been building globally: the same semaglutide molecule accumulating cardiovascular and liver outcomes data that widen the reimbursable population without new clinical development spending. Each added indication raises the ceiling on a single manufacturing base.
Shares of Novo Nordisk trade in Copenhagen and as American depositary receipts in New York under the ticker NVO. Investors will watch the company's next quarterly report for any China-specific revenue disclosure and for word on the oral Wegovy review timeline, which remains the larger volume opportunity given reluctance among some patients to use injections.
This article is for informational purposes only and does not constitute investment advice.
